Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Rituximab 48Cyclophosphamide 27Lenalidomide 23Peripheral Blood Stem Cell Transplantation 16obinutuzumab 10fludarabine phosphate 10Filgrastim 10Etoposide 10Bendamustine Hydrochloride 10Vincristine 8Prednisone 8Doxorubicin 8fludarabine 7Radiotherapy 7Mycophenolic Acid 7Melphalan 7Cyclosporine 7Bortezomib 7venetoclax 6tazemetostat 6ibritumomab tiuxetan 6Whole-Body Irradiation 6Gemcitabine 6pembrolizumab 5ibrutinib 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5CT-P10 5veltuzumab 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Follicular × prednisolone phosphate × Clear all
NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡